As we previously discussed, beginning in 2022, a series of patent infringement lawsuits were filed against Moderna and collaborators
Continue Reading mRNA/LNP Patent Litigation Update (Q1 2025)
Dan Shores is a partner at Rothwell, Figg and founder of its Boston office. He serves companies operating in dynamic biotech and other markets building patent portfolios, litigating complex patent disputes, negotiating strategic collaborations, and conducting due diligence and landscape investigations. Dan has served companies utilizing the following technologies (without limitation): mRNA; lipid nanoparticles; CAR-T; oligonucleotides; genetically engineered swine organs for xenotransplantation; artificial intelligence for drug discovery; small molecules; biologics, materials science, and numerous other technologies throughout his 20-year career. Dan has a B.S. in engineering with a specialization in materials science from the University of New Hampshire and a J.D. from the Georgetown University Law Center. He is a registered patent attorney licensed to practice before the United States Patent and Trademark Office, and is admitted to practice law in Massachusetts and in the District of Columbia. He is a member of the bars of the Supreme Court of the United States, United States Court of Appeals for the Federal Circuit, and United States District Court for the District of Massachusetts.
As we previously discussed, beginning in 2022, a series of patent infringement lawsuits were filed against Moderna and collaborators…
Continue Reading mRNA/LNP Patent Litigation Update (Q1 2025)In 1910, German scientist Paul Ehrlich introduced a groundbreaking concept to the world: chemical compounds could be engineered to interact…
Continue Reading Key Patent Considerations for Antibody Drug Conjugates (ADCs)The utilization of artificial intelligence (“AI”) is becoming ubiquitous across a wide range of industry sectors. The biotech industry is…
Continue Reading Key Inventorship Considerations in AI-assisted Drug DevelopmentAs I have written about previously, the IP and competitive landscape for mRNA and lipid nanoparticles is complex. Pioneers, mid-stage…
Continue Reading Advanced IP Considerations for Cell-and-Gene Therapeutic Companies Utilizing Lipid Nanoparticle Delivery SystemsSubstantial patent litigation activity occurred in the mRNA space in 2022, involving nearly all of the major mRNA and lipid…
Continue Reading mRNA IP 2022 Year in Review: Pioneers Clash in Major Patent LitigationsSeveral patent litigations have been filed involving mRNA pioneers such as Moderna, Inc. and BioNTech, Inc. (with Pfizer) over the…
Continue Reading The Current mRNA/LNP Patent Litigation Landscape
On August 16, 2022, Merck (NYSE: MRK) and Orna Therapeutics each announced that they entered into a collaboration agreement relating…
Continue Reading Merck and Orna Therapeutics Join Forces in Circular RNA Collaboration
In the first major patent infringement lawsuit in the mRNA space, on February 28, 2022, Arbutus Biopharma Corporation (“Arbutus”) and…
Continue Reading Arbutus and Genevant Sue Moderna in First Significant Patent Infringement Lawsuit in the mRNA Space
On January 4, 2022, Judge Andrews from the United States District Court for the District of Delaware denied Sarepta Therapeutics,…
Continue Reading Delaware Judge Denies Sarepta Protection Under Hatch-Waxman “Safe Harbor”
In April of 2021, we provided a three-part series relating to the IP and Competitive Landscape for the mRNA market.
Continue Reading mRNA Patent and Competitive Landscape: 2021 Year in Review and 2022 Outlook
We use cookies to enhance your user experience. By continuing to use this site you are giving your consent for us to use cookies. For more information, please see our Privacy Policy.